ACRS Aclaris Therapeutics Potential Buyout
ACRS Aclaris Therapeutics has 3 clinical trials releasing topline data this year and sufficient cash to fund their operations through the end of 2025.
ACRS is in Piper Sandler`s potential 12 biotech takeovers in 2023.
ACRS reached 52 week low today: $5.05.
Analysts Price Targets:
$21 The Goldman Sachs Group
$29 BTIG Research
$38 Cantor Fitzgerald
$43 HC Wainwright
Considering the above, I think ACRS might be an easy +3X!
Looking forward to read your opinion about it.
ACRS is in Piper Sandler`s potential 12 biotech takeovers in 2023.
ACRS reached 52 week low today: $5.05.
Analysts Price Targets:
$21 The Goldman Sachs Group
$29 BTIG Research
$38 Cantor Fitzgerald
$43 HC Wainwright
Considering the above, I think ACRS might be an easy +3X!
Looking forward to read your opinion about it.
BUYSELL indicators tradingindicators.store/
TRADING COURSE bit.ly/tradex
Private Signals www.patreon.com/PremiumOptionsSignals
RESULTS www.bit.ly/topgx
1%/DAY: bit.ly/3F56VTW
BYBIT partner.bybit.com/b/37880
TRADING COURSE bit.ly/tradex
Private Signals www.patreon.com/PremiumOptionsSignals
RESULTS www.bit.ly/topgx
1%/DAY: bit.ly/3F56VTW
BYBIT partner.bybit.com/b/37880